Is there a kink in consumers' threshold value for cost-effectiveness in health care?

被引:109
作者
O'Brien, BJ
Gertsen, K
Willan, AR
Faulkner, LA
机构
[1] St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON L8N 1G6, Canada
[2] Univ Nijmegen, Nijmegen, Netherlands
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
关键词
willingness to pay; willingness to accept; cost-effectiveness;
D O I
10.1002/hec.655
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: A reproducible observation is that Consumers' willingness-to-accept (WTA) monetary compensation to forgo a program is greater than their stated willingness-to-pay (WTP) for the same benefit. Several explanations exist, including the psychological principle that the utility of losses weighs heavier than gains. We sought to quantify the WTP-WTA disparity from published literature and explore implications for cost-effectiveness analysis accept-reject thresholds in the south-west quadrant of the cost-effectiveness plane (less effect, less cost)Methods: We reviewed published studies (health and non-health) to estimate the ratio of WTA to WTP for the same program benefit for each study and to determine if WTA is consistently greater than WTP in the literature. Results: WTA,WTP ratios were greater than unity for every study we reviewed. The ratios ranged from 3.2 to 89.4 for environmental studies (n = 7), 1.9 to 6.4 for health care studies (n = 2) 1.1 to 3.6 for safety studies (n = 4) and 13 to 2.6 for experimental studies (n = 7). Conclusions: Given that WTA is greater than WTP based on individual preferences, should not societal preferences used to determine cost-effectiveness thresholds reflect this disparity! Current convention in cost-effectiveness analysis is that any given accept-rejection criterion (e.g. $50 k/QALY gained) is symmetric - a straight line through the origin of the cost-effectiveness plane. The WTA-WTP evidence suggests a downward 'kink' through the origin for the south-west quadrant, such that the 'selling price' of a QALY is greater than the 'buying price'. The possibility of 'kinky cost-effectiveness' decision rules and the size of the kink merits further exploration. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [21] Cost-Effectiveness Threshold for Healthcare: Justification and Quantification
    Yanovskiy, Moshe
    Levy, Ori N.
    Shaki, Yair Y.
    Zigdon, Avi
    Socol, Yehoshua
    INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING, 2022, 59
  • [22] Cost-effectiveness of treatment for threshold retinopathy of prematurity
    Brown, GC
    Brown, MM
    Sharma, S
    Tasman, W
    Brown, HC
    PEDIATRICS, 1999, 104 (04) : e47
  • [23] Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists
    Bilinski, Alyssa
    MacKay, Evan
    Salomon, Joshua A.
    Pandya, Ankur
    VALUE IN HEALTH, 2022, 25 (07) : 1141 - 1147
  • [24] Modeling the Cost-Effectiveness of Health Care Systems for Alcohol Use Disorders: How Implementation of eHealth Interventions Improves Cost-Effectiveness
    Smit, Filip
    Lokkerbol, Joran
    Riper, Heleen
    Majo, Maria Cristina
    Boon, Brigitte
    Blankers, Matthijs
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2011, 13 (03) : e56
  • [25] The Cost-Effectiveness Analysis of an Integrated Mental Health Care Programme in Germany
    Mueller-Stierlin, Annabel Sandra
    Dinc, Uemmueguelsuem
    Herder, Katrin
    Walendzik, Julia
    Schuetzwohl, Matthias
    Becker, Thomas
    Kilian, Reinhold
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (11)
  • [26] Determination of a cost-effectiveness threshold for cancer interventions in Iran
    Safari, Hossein
    Poder, Thomas G.
    Afshari, Somayeh
    Nahvijou, Azin
    Arab-Zozani, Morteza
    Moradi, Nasrin
    Ameri, Hosein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] COST-EFFECTIVENESS OF SCREENING AND CRYOTHERAPY FOR THRESHOLD RETINOPATHY OF PREMATURITY
    JAVITT, J
    CAS, RD
    CHIANG, YP
    PEDIATRICS, 1993, 91 (05) : 859 - 866
  • [28] On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres, Laura
    Garcia-Lorenzo, Borja
    Castilla, Ivan
    Valcarcel-Nazco, Cristina
    Garcia-Perez, Lidia
    Linertova, Renata
    Polentinos-Castro, Elena
    Serrano-Aguilar, Pedro
    VALUE IN HEALTH, 2016, 19 (05) : 558 - 566
  • [29] Cytomegalovirus Screening in Pregnancy: A Cost-Effectiveness and Threshold Analysis
    Albright, Catherine M.
    Werner, Erika F.
    Hughes, Brenna L.
    AMERICAN JOURNAL OF PERINATOLOGY, 2019, 36 (07) : 678 - 687
  • [30] Cost, Effectiveness, and Cost-Effectiveness
    Diamond, George A.
    Kaul, Sanjay
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (01): : 49 - 54